Product Image

Contributor Information

  • Name Medical-Industrial Translational Research Center
  • Institute Fukushima Medical University
  • Primary citation Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176

Tool Details

  • Tool name: MCF10A-ERRB2m-13 cell line
  • Alternate names: 06M15027
  • Clone: ERBB2_type-15
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
  • Organism: Human
  • Tissue: Mammarygland epithelium
  • Cancer type: Non-tumorigenic
  • Morphology: Epithelial
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Type-15; Type mutation: P780_Y781insGSP; CDS mutation: c.2339_2340insGGGCTCCCC; AA mutation: p.P780_Y781insGSP; COSMIC Mutation ID: COSM12555
  • Application: Functional analysis of mutated genes, Drug screening
  • Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, ERBB2 (erb-B2 Receptor Tyrosine Kinase 2). ERBB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.
  • Research area: Cancer; Cell biology

  • For Research Use Only

Target Details

  • Target: Erb-b2 receptor tyrosine kinase 2 [ERBB2]
  • Target background: Gene ID: 2064; References: DNA (mRNA): NM_004448.3; Protein: NP_004439.2

Application Details

  • Application: Functional analysis of mutated genes, Drug screening


  • Format: Frozen
  • Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Âľg/ml insulin (human, recombinant), 5 ÂľM forskolin, 0.5 Âľg/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Âľg/ml streptomycin
  • Temperature: 37?C
  • Atmosphere: Humidified incubator with 5% CO2
  • Storage medium: CELLBANKER 2 (Zenogen pharma)
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests
  • Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
  • Cultured in antibiotics?: 100 U/ml Penicillin, and 100 Âľg/ml Streptomycin
  • Mycoplasma free: Yes
  • Biosafety level: 1


  • Available on request


  •   Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176